CASE REPORT

Primary diffuse large B cell lymphoma of the vulva—Two new cases of a rare entity and review of the literature

Alice L. Ye, BA, a Melissa S. Willis, MD, b Brian K. Link, MD, c Rachelle L. Naridze, MD, d Sergei I. Syrbu, MD, e and Vincent Liu, MD b,e
Maywood, Illinois; Iowa City, Iowa; and Marshfield, Wisconsin

Key words: diffuse large B-cell lymphoma; primary cutaneous non-Hodgkin lymphoma; vulvar lymphoma.

INTRODUCTION

With fewer than two dozen detailed cases reported in the literature, primary diffuse large B-cell lymphoma (DLBCL) of the vulva is a rare entity.

Although non-Hodgkin lymphomas (NHL) such as DLBCL most often arise from lymph nodes, bone marrow, or spleen, up to 24% of NHL can present primarily at extranodal sites such as the gastrointestinal tract and skin.  Less common is the occurrence of primary extranodal NHL at sites along the female genital tract.  Although disseminated lymphomas frequently involve structures within the female genital tract, only an estimated 1.5% of NHL are primary extranodal tumors of the female genital tract, anatomically reported in the following order of prevalence: ovary (49%), uterus (29%), fallopian tube (11%), vagina (7%), and vulva (4%). 1,2 Of these sites, DLBCL is the most common subtype of primary NHL identified within the female genital tract in general and in the vulva specifically. 3

We report 2 new cases of primary DLBCL of the vulva with associated literature review.

CASE REPORTS

Case 1

A 38-year-old HIV-negative woman from Iraq, gravida 2 para 2, presented with 1-week history of a vulvar ulceration, which yielded positive herpes simplex virus (HSV) 2 direct fluorescent-antibody, treated with valacyclovir. Over the next 8 months, slow enlargement of minimally tender nodular induration at the site prompted biopsy of an approximately 1- to 2-cm tumor.

Histopathology found dense sheets of large lymphoid cells staining positively for CD20, PAX-5, CD-79, Bcl-2, and MUM1, consistent with DLBCL, with features compatible with primary DLBCL, leg type (Fig 1). 4 No constitutional symptoms or lymphadenopathy were reported.

Positron emission tomography/computed tomography scan and bone marrow biopsy found no evidence of systemic involvement, yielding Ann Arbor stage IE. She underwent definitive localized radiation therapy (total dose of 36 Gy in 18 fractions followed by an electron boost to the vulva of 6 Gy) with remission of her disease, with continued remission 7 years later.

Case 2

A 73-year-old woman of European descent, gravida 2 para 2, presented with a 2-month history of a mass involving the clitoris and right anterior aspect of the labium minus, measuring 4 × 2 × 1.5 cm. Initial biopsy found a dense lymphoid infiltrate composed

---

From the Loyola University Chicago Stritch School of Medicine a, the Departments of Dermatology, b Internal Medicine - Hematology, Oncology and Blood and Marrow Transplantation, c and Pathology, d University of Iowa; and The Marshfield Clinic, Marshfield, e

Funding sources: None.
Conflicts of interest: None disclosed.
Correspondence to: Vincent Liu, MD, 40035 Pomerantz Family Pavilion, 200 Hawkins Drive, Iowa City, IA 52242. E-mail: vincent-liu@uiowa.edu.

JAAD Case Reports 2018;4:962-7.
2352-5126 © 2018 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2018.06.023
of CD20⁺ lymphocytes featuring medium- to large-sized centroblastlike cells, co-expressing Bcl-2, CD23, and weak CD10, but not Bcl-6, CD3, CD5, or cyclin D1. Wide excision of the lesion 3 weeks later found large cells in a vaguely nodular pattern (Fig 2) staining positively for CD20, CD10, Bcl-2, Bcl-6, and MIB-1 (60%) but negatively for MUM1 and Epstein-Barr encoding region, interpreted as DLBCL, germinal center B-cell (GCB) type.

Bone marrow biopsy and 18F-fluorodeoxyglucose positron emission tomography-computed tomography scan found no further evidence of malignancy, yielding Ann Arbor Stage IE. No further therapy was administered. No systemic disease has been seen by computed tomography imaging during surveillance up to 65 months from diagnosis.

**DISCUSSION**

These 2 cases add experience with primary vulvar DLBCL to our limited literature to date, thereby expanding our understanding of this poorly characterized condition. Our cases share the similar clinical presentation of a localized enlarging mass, with the first case notably preceded by herpetic infection. Pathologically, both cases manifested classic DLBCL architecture and cytomorphology; by immunohistochemistry, the first case exhibited a profile more in keeping with classic leg type primary cutaneous DLBCL (MUM-1 positive), whereas the second case qualified as a GCB-type DLBCL (CD10 and Bcl-6 positive). Both cases shared good response to local therapy.

Review of the literature on primary vulvar DLBCL is limited by small numbers and retrospective nature of reports, variably detailed immunohistochemical
| Patient number | Reference | Age | PMH | Clinical presentation | Size | Ann Arbor stage | Histopathology | Initial treatment | Outcomes |
|----------------|-----------|-----|-----|-----------------------|------|----------------|----------------|------------------|----------|
| 1              | Ye et al, 2018, current report | 38  | G2P2, Iraqi | Valacyclovir-treated initial HSV ulceration preceded growth of underlying nodule | 1-2 cm | IE | PCDLBCL-LT | RT | AWOD at 7 y |
| 2              | Ye et al, 2018, current report | 73  | G2P2, European descent | 2-mo history of enlarging mass | $4 \times 2 \times 1.5$ cm | IE | DLBCL (GCB-type) | Local excision | AWOD at 65 mo |
| 3              | Clement et al, 2016 | 43  | Recurrent pseudolymphoma of inguinal region, nulliparous, tobacco user | 6-mo history of nontender, movable mass | 3.2 cm | IIE | DLBCL (GCB-type) | Local excision, followed by 6 cycles of R-CHOP with CR | Remission at 6 mo |
| 4              | El Kacemi et al, 2015 | 37  | Primiparous | Pruritic, painful, ulcerating mass | $13 \times 7$ cm | IIE | DLBCL | 4 cycles of R-CHOP, followed by RT with CR | AWOD at 36 mo |
| 5              | Plaza et al, 2011 | —   | —   | No evidence of extracutaneous disease | — | IE | PC-DLBCL (NOS) | — | — |
| 6              | Signorelli et al, 2007 | 75  | —   | — | — | IIE | DLBCL | 5 cycles of CHOP with CR | Recurrence at 10 mo. Given additional 4 cycles R-CHOP with CR. AWOD at 21 mo |
| 7              | Kosari et al, 2005 | >19 | —   | — | — | Localized — unknown staging | DLBCL | — | — |
| 8              | Tjalma et al, 2002 | 73  | TAH & unilateral SO for myomas, nulliparous, HIV negative | 5-mo history of enlarging mass | $3 \times 1.5$ cm | IE | DLBCL | Local excision, followed by RT with CR | Recurrence at 6 mo. Given additional 6 cycles CHOP with CR. AWOD at 51 mo |
| 9              | Vang et al, 2001 | 67  | —   | Pruritic mass | — | IIE | DLBCL | CT and RT with CR | Recurrence in spine. DOD at 2 y |
| 10             | Vang et al, 2001 | 71  | —   | Mass | — | IE | DLBCL | — | — |
| 11             | Vang et al, 2001 | 68  | —   | Mass with ulceration 7 cm | 7 cm | Unknown | DLBCL | — | — |
|   | Reference | Case Details | Clinical Features | Pathology | Treatment | Outcome |
|---|------------|--------------|-------------------|-----------|-----------|---------|
| 12 | Iczkowski et al, 2000 | White, G1P1, TAHBSO for leiomyomas & adenomyosis | Localized erythema and swelling with nontender induration and overlying ulceration; No evidence of extracutaneous disease | DLBCL | CHOP with CR | AWOD at 12 mo |
| 13 | Macleod et al, 1998 | Multiparous, TAHBSO for benign tumor | 2-y history of pruritic right anterior labium minus mass and underwent excision with local recurrence 6 mo later | IE DLBCL | Local excision and RT with CR | AWOD at 30 mo |
| 14 | Kaplan et al, 1996 | African American, HIV+, laser genital wart removal 8 mo prior | 3-mo history of painful, edematous mass with overlying ulceration; 20lb weight loss over prior 6 mo | IE DLBCL | 3 cycles modified low dose CHOP-bleomycin without significant response. Switched to RT with partial response | DOD at 7 mo |
| 15 | Marcos et al, 1992 | Multiparous | 1-mo history of enlarging, nonpainful mass | IE DLBCL | RT with CR | AWOD at 10 mo |
| 16 | Nam et al, 1992 | Korean, multiparous | 1-y history of movable, nontender mass | IE DLBCL | Local excision | AWOD at 14 mo |
| 17 | Bagella et al, 1990 | — | Mass with surrounding edema | — IE DLCL | Local excision, PROVECIP with CR | DWD at 10 mo due to unknown cause |
| 18 | Sneddon and Wishart, 1972 | 7-y history of dermatomyositis and recently started on azathioprine | 3-mo history of dyspareunia with vulvar ulceration and vaginal discharge | — Unknown DLCL (reticulum cell sarcoma) | RT | AWOD at 10 mo |
| 19 | Schiller et al, 1970 | — | Vulvar lesion | — Unknown DLCL (reticulum cell sarcoma) | — | — |

Continued
| Patient number | Reference          | Age | PMH                          | Clinical presentation                                                                 | Size      | Ann Arbor stage | Histopathology                                  | Initial treatment                      | Outcomes                        |
|----------------|--------------------|-----|------------------------------|---------------------------------------------------------------------------------------|-----------|-----------------|------------------------------------------------|--------------------------------------|----------------------------------|
| 20             | Iliya et al, 1968  | 75  | —                            | Mass                                                                                   | 3 cm      | Unknown         | DLCL (reticulum cell sarcoma)                    | Excision                            | AWOD at 5 y                     |
| 21             | Buckingham & McClure, 1955 | 33 | African American, nulligravida | 2-wk history of rapidly enlarging, ulcerated mass; 50-lb weight loss over unknown period | 14 cm     | Unknown         | DLCL (reticulum cell sarcoma or lymphosarcoma)   | Local excision and RT with partial response | AWD at 6 mo                     |
| 22             | Taussig, 1937      | 63  | Multiparous                  | 8-mo history of enlarging, nontender mass with overlying ulceration and associated bleeding, weight loss of 8 lb over previous year | 2 × 1.5 cm | Unknown         | DLCL (lymphosarcoma)                             | Local excision                       | Died 15 days post-op due to presumptive PE |

AWD, Alive with disease; AWOD, alive without disease; CR, complete remission; CT, chemotherapy; DLBCL, diffuse large B-cell lymphoma; DLCL, diffuse large cell lymphoma; DOD, died of disease; DWD, died with disease; PCDLBCL-LT, primary cutaneous diffuse large B-cell lymphoma — leg type; PCDLBCL (NOS), primary cutaneous diffuse large B-cell lymphoma — not otherwise specified; PMH, past medical history; PROVECIP, vinblastine, procarbazine, prednisone; RT, radiation therapy; SO, salpingo-oophorectomy; TAH, total abdominal hysterectomy.
analysis and application of now obsolete classifications; nevertheless, some clues as to the nature of the condition emerge in the context of known cases. Search of PubMed/Medline English-language literature databases identified 20 additional cases of apparent localized vulvar masses with DLBCL or likely DLBCL diagnosis (stage I/II) (Table I).

Based on our case review, primary vulvar DLBCL is a condition affecting women with a mean age of 58, a median age of 64, range of 25 to 79, bimodally distributed between 25 and 43 and 61 to 79, with an average length of follow-up of 28 months (Table I). Based on 20 of 22 cases of vulvar DLBCL that reported clinical presentations, 8 of 20 cases (40%) presented with ulceration, 30% with enlarging mass, and 25% with nontender mass. Pruritus, erythema, and edema have also been described.

When placed in the context of prior reported cases of primary vulvar DLBCL, our cases appear to fit a larger narrative of frequently treatment-responsive disease with good initial prognosis (Table I). Generally, management of primary vulvar DLBCL has included excision, radiotherapy, and chemotherapy, each alone and in combination, without clear superiority of any specific therapeutic intervention. Including the current cases, of the 22 patients reviewed in the literature, 2 are reported to have died of disease. One was a 25-year-old HIV-positive woman presenting with an ulcerated large (up to 12 cm) mass with concurrent weight loss. She had stage IE disease that did not respond to low-dose cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP)-bleomycin and only partially responded to radiotherapy. The patient died 7 months after diagnosis. The other was a 67-year-old woman with stage IIE DLBCL manifesting as a pruritic mass that achieved complete response with chemotherapy and radiation therapy. The disease was followed by recurrence in the spine, and the patient died 2 years after the initial diagnosis. Dissecting the data further, the 25-year-old woman who died of disease represented 1 of 2 response patients who experienced only a partial response to chemotherapy, each alone and in combination, comprising 12.5% of the total cases with reported outcomes (2 of 16). Both of these partial-response patients were notably younger and African American and had bulky, ulcerated tumors of 10 cm or larger, features which may portend adverse prognosis.

Of note, the vulva, situated at a unique interface between skin and mucosal lymphoid tissue, represents a site of DLBCL presentation whose accurate categorization as primary cutaneous or nodal is uncertain. Our 2 additional patients, reviewed in the context of the available literature, add to the characterization of vulvar DLBCL as a lymphoma affecting a broad age range, with variably nodular presentations, and with a generally good initial response to treatment.

REFERENCES

1. Signorelli M, Maneo A, Cammarota S, et al. Conservative management in primary genital lymphomas: the role of chemotherapy. Gynecol Oncol. 2007;104(2):416-421.
2. Bagella MP, Fadda G, Cherchi PL. Non-Hodgkin lymphoma: a rare primary vulvar localization. Eur J Gynaecol Oncol. 1990;11(2):153-156.
3. Vang R, Medeiros LJ, Fuller GN, Sarris AH, Deavers M. Non-Hodgkin’s lymphoma involving the gynecologic tract: a review of 88 cases. Adv Anat Pathol. 2001;8(4):200-217.
4. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
5. Clemente N, Alessandrinli L, Rupolo M, et al. Primary Non-Hodgkin’s Lymphoma of the Vulva: A Case Report and Literature Review. Medicine (Baltimore). 2016;95(10):e3041.
6. El Kacemi H, Lahy I, Kebdani T, Benjaafar N. Primary non-Hodgkin lymphoma of the vulva in an immunocompetent patient. J Cancer Res Ther. 2015;11(3):657.
7. Plaza JA, Kacerovska D, Stockman DL, et al. The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases. Am J Dermatopathol. 2011;33(7):649-655.
8. Kosari F, Daneshbod Y, Parwaresch R, Krams M, Wacker HH. Lymphomas of the female genital tract: a study of 186 cases and review of the literature. Am J Surg Pathol. 2005;29(11):1512-1520.
9. Tjalma WA, Van de Velde AL, Schroyens WA. Primary non-Hodgkin’s lymphoma in Bartholin’s gland. Gynecol Oncol. 2002;87(3):308-309.
10. Iczkowski KA, Han AC, Edelson MI, et al. Primary, localized vulvar B-cell lymphoma expressing CD44 variant 6 but not cadherins. A case report. J Reprod Med. 2000;45(10):853-856.
11. MacLeod C, Palmer A, Findlay M. Primary non-Hodgkin’s lymphoma of the vulva: A case report. Int J Gynecol Cancer. 1998;8:504-508.
12. Kaplan EJ, Chadburn A, Caputo TA. HIV-related primary lymphoma of the vulva. Gynecol Oncol. 1996;61:131-138.
13. Marcos C, Martinez L, Esquivias JJ, et al. Primary non-Hodgkin lymphoma of the vulva. Acta Obest Gynecol Scand. 1999;71(4):298-300.
14. Nam JH, Park MC, Lee KH, et al. Primary non-Hodgkin’s malignant lymphoma of the vulva — a case report. J Korean Med Sci. 1992;7(3):271-275.
15. Sneddon I, Wishart JM. Immunosuppression and malignancy. Br Med J. 1972;4(5834):235.
16. Schiller HM, Madge GE. Reticulum Cell Sarcoma Presenting as a Vulvar Lesion. South Med J. 1970;63(4):471-472.
17. Iliya FA, Muggia FM, O’Leary JA, et al. Gynecologic manifestations of reticulum cell sarcoma. Obstet Gynecol. 1968;31(2):266-269.
18. Buckingham JC, McClure JH. Reticulum cell sarcoma of the vulva — report of a case. Obstet Gynecol. 1955;62(2):138-143.
19. Taussig FJ. Sarcoma of the vulva. Am J Obstet Gynecol. 1937;33:1017-1026.